Core Insights - Dermata Therapeutics is shifting its strategy to focus on developing and commercializing over-the-counter (OTC) skin care treatments [1] - The company plans to launch its first OTC product, a once-weekly acne kit utilizing its Spongilla technology, in mid-2026 [1] - Dermata reported financial results for the third quarter ended September 30, 2025, highlighting recent corporate progress [1] Company Developments - Dermata is positioned as a science-driven leader in dermatologic solutions [1] - The company's mission emphasizes delivering scientifically developed innovations to those in need [1]